Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening

Journal of Hepatology

Volumn 50, Issue 5, 2009, Pages 990-998

  Robotin, Monica C ^a,b   Kansil, Melanie ^c   Howard, Kirsten ^b   George, Jacob ^d,e   Tipper, Steven ^a   Dore, Gregory J ^f   Levy, Miriam ^g   Penman, Andrew G ^a  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Pacific Strategy Partners   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g LIVERPOOL HOSPITAL   (Australia)

Author keywords

Chronic hepatitis B; Cost effectiveness; Disease surveillance; Hepatocellular cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASIAN; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CANCER; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; OUTCOME ASSESSMENT; POPULATION RISK; PRIORITY JOURNAL; PROBABILITY; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASIA; AUSTRALIA; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; POPULATION SURVEILLANCE; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 64549122996     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.12.022     Document Type: Article

References (48)

1. McDermid I. Cancer incidence projections, Australia 2002 to 2011. Canberra: Australian Institute of Health and Welfare (AIHW), Australasian Association of Cancer Registries (AACR) and the National Cancer Strategies Group (NCSG); 2005.
2. Coates M., and Tracey E. Cancer in New South Wales: incidence and mortality 1997. NSW Public Health Bull 12 (2001) 40-42
3. Supramaniam R., O'Connell D.L., Tracey E., and Sitas F. Cancer incidence in New South Wales migrants 1991 to 2001 (2006), The Cancer Council NSW, Sydney
4. Bosch F.X., Ribes J., Diaz M., and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
5. Chan H.L., and Sung J.J. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 26 (2006) 153-161
6. Fung S.K., and Lok A.S. Treatment of chronic hepatitis B: who to treat, what to use, and for how long?. Clin Gastroenterol Hepatol 2 (2004) 839-848
7. Hache C., and Villeneuve J.P. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin Pharmacother 7 (2006) 1835-1843
8. Lai C.J., and Terrault N.A. Antiviral therapy in patients with chronic hepatitis B and cirrhosis. Gastroenterol Clin North Am 33 (2004) 629-654
9. Lok A.S., and McMahon B.J. Chronic hepatitis B: update of recommendations. Hepatology 39 (2004) 857-861
10. Gellert L., Jalaludin B., and Levy M. Hepatocellular carcinoma in Sydney South West: late symptomatic presentation and poor outcome for most. Intern Med J 37 (2007) 516-522
11. Commonwealth Department of Health and Ageing. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.1). editor: Commonwealth of Australia; Canberra, ACT; 2006.
12. Dore G, Wallace J, Locarnini S, Desmond P, Gane E, Crawford DH. Hepatitis B in Australia: responding to a diverse epidemic. Sydney: Australasian Society for HIV Medicine; 2006. Available from: http://www.ashm.org.au/uploads/Hep-B-in-Australia.pdf
13. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2007. Sydney, NSW: National Centre in HIV Epidemiology and Clinical Research; 2007.
14. Keeffe E.B., Dieterich D.T., Han S.H., Jacobson I.M., Martin P., Schiff E.R., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 (2006) 936-962
15. Liaw Y.F., Leung N., Guan R., Lau G.K., Merican I., McCaughan G., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 25 (2005) 472-489
16. Thomas H.C. Best practice in the treatment of chronic hepatitis B: a summary of the European Viral Hepatitis Educational Initiative (EVHEI). J Hepatol 47 (2007) 588-597
17. Yuen M.F., Yuan H.J., Hui C.K., Wong D.K., Wong W.M., Chan A.O., et al. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 52 (2003) 416-419
18. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 39 (2003) 1076-1084
19. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 295 (2006) 65-73
20. Sherman M. Pathogenesis and screening for hepatocellular carcinoma. Clin Liver Dis 8 (2004) 419-443
21. Villeneuve J.P. The natural history of chronic hepatitis B virus infection. J Clin Virol 34 Suppl 1 (2005) S139-S142
22. Kanwal F., Gralnek I.M., Martin P., Dulai G.S., Farid M., and Spiegel B.M. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 142 (2005) 821-831
23. Shepherd J., Jones J., Takeda A., Davidson P., and Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 10 (2006) 1-183
24. Yang B., Zhang B., Xu Y., Wang W., Shen Y., Zhang A., et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 123 (1997) 357-360
25. Australian Bureau of Statistics. Statistics; 2008. Website: http://www.abs.gov.au/ Accessed December 2, 2008.
26. Commonwealth Department of Health and Ageing. Medicare Benefits Schedule book. In: Ageing CDoHa, editor. Canberra, ACT: Commonwealth of Australia; 2007.
27. Commonwealth Department of Health and Ageing. Schedule of Pharmaceutical Benefits for approved pharmacists and medical practitioners. editor Commonwealth of Australia; 2007. Canberra, ACT.
28. Commonwealth Department of Health and Ageing. National Hospital Cost Data Collection. Cost Report Round 10 (2005-6) AR-DRG v5.0. editor. Commonwealth Department of Health and Ageing; 2007. Canberra, ACT.
29. Shepherd J., Jones J., Takeda A., Davidson P., and Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 10 (2006) 1-183
30. Thompson Coon J., Rogers G., Hewson P., Wright D., Anderson R., Cramp M., et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 11 (2007) 1-206
31. Bowel cancer screening pilot monitoring and evaluation Steering Committee. Australia's bowel cancer screening pilot and beyond. Final evaluation report Canberra: Australian Government, Department of Health and Ageing; 2005.
32. George B., Harris A., and Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19 (2001) 1103-1109
33. Nguyen M.H., and Keeffe E.B. Screening for hepatocellular carcinoma. J Clin Gastroenterol 35 (2002) S86-S91
34. Yuen M.F., and Lai C.L. Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol 14 (2003) 1463-1467
35. Wun YT, Dickinson JA. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. Cochrane Database Syst Rev 2003: CD002799.
36. Zhang B.H., Yang B.H., and Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130 (2004) 417-422
37. Fung J., Gane E., Bullen C., Hornell J., and McCall J. Improved survival with screening for hepatocellular carcinoma in chronic hepatitis B: preliminary results of a national surveillance programme. Hepatology 40 (2004) 258A
38. Gane E. Screening for chronic hepatitis B infection in New Zealand: unfinished business. NZ Med J 118 (2005) U1344
39. Arguedas M.R., Chen V.K., Eloubeidi M.A., and Fallon M.B. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 98 (2003) 679-690
40. Lin O.S., Keeffe E.B., Sanders G.D., and Owens D.K. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 19 (2004) 1159-1172
41. Nouso K., Tanaka H., Uematsu S., Shiraga K., Okamoto R., Onishi H., et al. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol 23 (2008) 437-444
42. Thompson Coon J., Rogers G., Hewson P., Wright D., Anderson R., Jackson S., et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 98 (2008) 1166-1175
43. Dusheiko G.M., and Roberts J.A. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 22 (1995) 1863-1873
44. Wong J.B., Koff R.S., Tine F., and Pauker S.G. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 122 (1995) 664-675
45. Hutton D.W., Tan D., So S.K., and Brandeau M.L. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 147 (2007) 460-469
46. Cameron A.J., Welborn T.A., Zimmet P.Z., Dunstan D.W., Owen N., Salmon J., et al. Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 178 (2003) 427-432
47. Australian and New Zealand Liver Transplant Registry. Australian and New Zealand Liver Transplant Registry Report 2004. Brisbane: ANZLT; 2005.
48. Yuen M.F. Revisiting the natural history of chronic hepatitis B: impact of new concepts on clinical management. J Gastroenterol Hepatol 22 (2007) 973-976